Ege David S.'s Form 4 filing
Seres Therapeutics, Inc. (MCRB) · filed Oct 31, 2023
- Accession no.
- 0000899243-23-020075
- Filed
- Oct 31, 2023
- Trade date
- Apr 27-Oct 30, 2023
- Filing delay
- 187 daysLate
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market sales total $5.49K. It was filed 187 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ege David S.CIK 0001829360 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 27, 2023 | Common Stock | MOption exerciseAcquired | +11,361 | $0.00 | $0 | 71,057 | Direct | |
| Oct 30, 2023 | Common Stock | SSaleDisposed | −4,066 | $1.35F3 | −$5,489.1 | 66,991 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 27, 2023 | Common Stock | AGrant or awardAcquired | +22,721 | $0.00 | $0 | 22,721 | Direct | |
| Oct 27, 2023 | Common Stock | MOption exerciseDisposed | −11,361 | $0.00 | $0 | 11,360 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.3425 to $1.405, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
Executive Vice President and Chief Technology Officer